EGFR mutations underlie the responsiveness of NSCLC to gefitinib

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1451, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib, vinorelbine and EGFR mutations in lung cancer

Inpharma, Vol. 1, Iss. 1590, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

INTEREST piqued with gefitinib in NSCLC

Inpharma, Vol. 1, Iss. 1666, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Gefitinib shows promise in NSCLC

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Gefitinib of value in NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 625, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite